Manufacturing progress, stability data, and formulation advances are moving Lakewood-Amedex’s lead antimicrobial candidate closer to Phase 2 testing in infected diabetic foot ulcers.
Key Investor Takeaways
- The primary catalyst is positive Nu-3 data supporting advancement toward a planned Phase 2 clinical trial
- Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) reported manufacturing and formulation progress for its Bisphosphocin® antimicrobial platform
- The company completed multikilogram cGMP manufacturing runs for both Nu-3 drug substance and gel formulation
- Stability testing showed Nu-3 drug substance remained stable for at least five years, while the gel formulation demonstrated two-year stability
- Management highlighted broader future applications for the Bisphosphocin® platform beyond diabetic foot ulcers, including urinary tract and pulmonary infections
Why LABT Stock Is in Focus
Lakewood-Amedex Biotherapeutics announced positive development and manufacturing data for Nu-3, its lead antimicrobial candidate targeting mildly infected diabetic foot ulcers.
According to the company, it completed several multikilogram manufacturing runs for members of the Bisphosphocin® class under current Good Manufacturing Practices guidelines.
The company also said it successfully manufactured multikilogram quantities of the Nu-3 gel formulation suitable for use in future clinical trials.
Management noted that process improvements reduced production costs while enhancing physical chemistry characteristics of the drug substance.
“Lakewood-Amedex Biotherapeutics has worked diligently to optimize formulation and manufacturing processes required to produce both the Bisphosphocin® drug substances and drug products,” said Kelvin Cooper, Ph.D., Chief Executive Officer at Lakewood-Amedex Biotherapeutics.
The company reported that stability testing showed the Nu-3 drug substance remained stable for at least five years, while the final gel formulation remained stable for at least two years.
Lakewood-Amedex also stated that initial antimicrobial effectiveness testing showed undetectable bioburden levels without requiring additional preservatives.
Nu-3 is designed as a topical antimicrobial treatment for infected diabetic foot ulcers with a goal of reducing antimicrobial resistance risks.
According to the company, the Bisphosphocin® platform demonstrated the ability in vitro to rapidly eliminate bacteria through destabilization of bacterial cell membranes, including resistant strains such as MRSA and VRE.
Why This Matters for Investors
The announcement may be important for investors because it shifts focus from early-stage discovery toward operational readiness for later-stage clinical development.
Manufacturing scalability, formulation stability, and cGMP production capabilities are often critical hurdles for clinical-stage biotechnology companies preparing for larger trials and eventual commercialization efforts.
The extended stability profile may also support future supply chain flexibility and commercial manufacturing potential if clinical development progresses successfully.
Beyond diabetic foot ulcers, management is also positioning the Bisphosphocin® platform as a broader antimicrobial technology with potential applications across additional infectious disease indications.
That broader platform narrative could become increasingly relevant as investors continue monitoring antimicrobial resistance and demand for alternative anti-infective therapies.
However, the company remains in the clinical development stage, and Nu-3 has not yet demonstrated efficacy in larger late-stage trials.
Future regulatory outcomes, clinical results, safety performance, and commercialization execution remain key uncertainties.
What to Watch Next
Investors may monitor:
- Timing and initiation of the planned Phase 2a Nu-3 clinical trial
- Dose-response and safety data from upcoming studies
- Potential expansion into additional infectious disease indications
- Further manufacturing scale-up and commercialization readiness updates
- Regulatory interactions tied to Nu-3 development and trial progression